Forest Celexa
Executive Summary
Citalopram co-promotion agreement with Warner-Lambert will be terminated immediately, Forest announces May 12. Forest will pay Warner-Lambert $14 mil. to terminate the agreement and Warner-Lambert will be excluded from any profits recorded after April 30. Forest reported earlier in May that its sales force has been expanded from 850 to 1,425 representatives, resulting in a decrease of net income for the quarter ending March 31. Warner-Lambert's merger partner Pfizer markets the competing antidepressant Zoloft. The termination agreement contains provisions "limiting Warner-Lambert employees previously involved in marketing or selling Celexa from marketing or selling" Zoloft for a specified period of time, Forest said
You may also be interested in...
Forest Aerobid Non-CFC Asthma Inhaler Launch Expected In Fall, C0O Says
Forest will launch its non-CFC version of the prescription asthma inhaler Aerobid (flunisolide) this fall, President and Chief Operating Officer Kenneth Goodman told analysts on a conference call Jan. 16.
Forest Aerobid Non-CFC Asthma Inhaler Launch Expected In Fall, C0O Says
Forest will launch its non-CFC version of the prescription asthma inhaler Aerobid (flunisolide) this fall, President and Chief Operating Officer Kenneth Goodman told analysts on a conference call Jan. 16.
Forest Celexa Sales Reach $150 Mil. For Quarter; Sales Support Steps Up
Forest's internal sales effort for the antidepressant Celexa has exceeded the peak sales effort during the co-promotion period with Warner-Lambert, the company maintains.